<DOC>
	<DOCNO>NCT00813709</DOCNO>
	<brief_summary>REFLEXION double blind extension study 27025 ( NCT00404352 ) ( REFLEX ) . The purpose study obtain long-term follow-up data subject clinically definite multiple sclerosis ( MS ) subject first demyelinate event high risk convert MS , treat fetal bovine serum [ FBS ] -free/human serum albumin [ HSA ] -free formulation interferon [ IFN ] -beta-1a ( RNF ) .</brief_summary>
	<brief_title>Long-term Follow-Up Patients Who Participated Study 27025 ( REFLEX )</brief_title>
	<detailed_description>The objective study investigate whether RNF treatment initiate first clinical event versus delay treatment result prolongation time Clinically Definite Multiple Sclerosis ( CDMS ) conversion Month 36 Month 60 since randomization Study 27025 ( REFLEX ) . Furthermore , study intend explore whether RNF treatment initiate first clinical event versus delayed treatment delay disability ( include development secondary progressive MS ) reduce disease activity ( include annual relapse rate [ ARR ] ) long term ( Month 36 Month 60 since randomization Study 27025 ( REFLEX ) . The study also assess long-term safety profile RNF ( Month 36 Month 60 since randomization Study 27025 ( REFLEX ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Reach schedule end study Study 27025 ( REFLEX ) ( completion 24 month participation ) Medical assessment Investigator/treating physician study 27025 objection subject 's participation extension trial consider medical experience Study 27025 ( REFLEX ) . Special attention give laboratory abnormality clinically significant liver , renal bonemarrow dysfunction If female , subject must : neither pregnant breastfeeding , attempt conceive use highly effective method contraception . A highly effective method contraception define result low failure rate ( [ i.e . ] less 1 percent [ % ] per year ) use consistently correctly implant , injectables , combine oral contraceptive , intrauterine device ( IUDs ) , sexual abstinence vasectomize partner Subject willing follow study procedure Subject give write informed consent Subject disease MS could better explain subject 's sign symptom Subject primary progressive course MS Subject total bilirubin great 2.5 time upper limit normal ( ULN ) Month 24 previous visit ( i.e . Month 21 ) ( subject great 2.5 time ULN Month 24 eligible enrollment manage per label recommendation normalization value ) Subject total aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) alkaline phosphatase ( ALP ) great 2.5 time ULN value Month 24 previous visit ( i.e . Month 21 ) ( subject great 2.5 time ULN Month 24 eligible enrollment manage per label recommendation normalization value ) Subject suffer another current autoimmune disease Subject suffer major medical psychiatric illness ( include history , current , severe depressive disorder and/or suicidal ideation ) opinion investigator create undue risk subject could affect compliance study protocol Subject history seizure adequately control treatment Subject cardiac disease , angina , congestive heart failure arrhythmia Subject know allergy IFNbeta excipient ( ) study medication Subject condition could interfere MRI evaluation Subject know allergy gadoliniumdiethylene triamine pentaacetic acid ( DTPA ) Subject history alcohol drug abuse Subject previously participate study Subject moderate severe renal impairment Subject pregnant lactating Subject medical , psychiatric condition compromise his/her ability understand subject information , give informed consent , comply study protocol , complete study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Interferon 1-beta</keyword>
	<keyword>Clinical Definite Multiple Sclerosis</keyword>
</DOC>